Intangible Assets

NEOV does not appear to have a durable brand, patent, or regulatory franchise that lets it charge materially better pricing than peers, so intangible assets do not support long-run margin power.

The available metrics show deeply negative ROIC and ROCE, which is inconsistent with an asset-backed or IP-backed advantage that would persist versus peers.

No evidence in the provided data indicates proprietary data, clinical exclusivity, or other protected assets that would create peer-dependent demand or retention.

Compared with stronger healthcare or medtech peers that rely on patents, reimbursement protection, or entrenched clinical workflows, NEOV’s intangible moat appears limited and replicable.

Switching Costs

The negative ROIC and long cash conversion cycle suggest customers are not locked in by high switching friction, because the business is not converting capital into durable retained returns.

There is no evidence of embedded workflow dependence, regulatory lock-in, or contractual stickiness that would make replacement costly versus peers.

Compared with peers that benefit from installed-base consumables, software integration, or recurring clinical protocols, NEOV shows little sign of retention-driven pricing power.

The provided metrics do not support a moat built on customer inertia, so switching costs look low and easily replicable.

Network Effects

The available information does not show a user, data, or ecosystem loop that would make the product more valuable as adoption rises.

Negative profitability and weak capital efficiency argue against a self-reinforcing platform dynamic that compounds versus peers.

Unlike peer businesses with referral, marketplace, or data-network effects, NEOV shows no evidence of cross-user or cross-site reinforcement.

There is no sign that customers depend on the platform for core industry operation, so network effects appear absent.

Cost Advantage

ROIC and ROCE are materially negative, which indicates NEOV is not demonstrating a structural cost advantage versus peers in converting investment into returns.

A cash conversion cycle near 189 days suggests working-capital intensity rather than a lean operating model that would support lower unit costs.

The asset turnover level does not offset the weak return profile, so efficiency is not translating into a durable cost edge.

Compared with peers that benefit from scale purchasing, manufacturing leverage, or process efficiency, NEOV does not show evidence of a persistent cost moat.

Efficient Scale

The provided data do not indicate that NEOV operates in a niche where one or two players can serve the market efficiently enough to deter entry.

Negative returns imply the company is not capturing the economics of a protected scale position versus peers.

There is no evidence of regulated capacity limits, exclusive distribution, or infrastructure bottlenecks that would create efficient-scale protection.

Compared with peers in concentrated markets, NEOV does not appear to benefit from a structurally scarce market position that would sustain pricing power.

Overall Score

NEOV’s moat appears weak versus peers because the available metrics show negative capital returns, poor working-capital efficiency, and no evidence of durable intangible assets, switching costs, network effects, cost advantage, or efficient-scale protection.